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SIR- Recessive mutations in the IL36RN gene, encoding interleukin 36 receptor 
antagonist (IL-36Ra), have illuminated the understanding of the pathogenesis of 
generalized pustular psoriasis (GPP).1,2 Consanguineous Tunisian families were 
central to the discovery of homozygous mutations in IL36RN being associated with 
early onset GPP.2 Studies in populations from different genetic backgrounds 
highlighted the requirement of other genes in cases that are mutation negative, or 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
only carry a mutation in a single allele.3 Sibling pairs with compound heterozygote 
mutations in European and Asian populations, an intriguing, non-consanguineous, 
genetic background to study phenotypes associated with IL36RN, are rare. 
Furthermore, the genetic differences in autozygosity seen in consanguineous 
families are currently being delineated at a population level, and support the 
exploration and comparison of phenotypes seen in this genetic background with 
other non-consanguineous genetic backgrounds.4 Only 1 compound heterozygous 
case of Japanese twins is reported as affected siblings. In this case, both twins 
developed GPP at the age of 2, following treatment with amoxicillin. Siblings with 
homozygous IL36RN mutations have been reported to present within 11 years of 
each other (Supplementary Table 1a). Here we present a report of two sisters that 
carry identical compound heterozygous mutations in IL36RN, yet first presented 34 
years apart, exemplifying the requirement of further genetic or environmental factors.  
A 38-year-old, female, European patient had been attending our department 
with features consistent with severe GPP since 6 months of age. Widespread small 
pustules were seen on the trunk and limbs, and numerous hospital admissions with 
severe pustulation and fever were a recurrent feature of childhood (Figure 1a). The 
patient’s history was negative for recognised triggers of GPP such as antibiotic 
usage, infection and menstruation.  Histological examination of the sterile pustules 
demonstrated a brisk neutrophillic infiltrate, with some spongiosis  (Figure 1d). 
Acrodermatitis continuua of Hallopeau involving the fingernails prevented nail 
growth. Extensive scalp involvement could not be controlled such that the patient 
resorted to wearing a hat. Pustules were seen on the oral mucosa during severe 
flares and widespread lymphadenopathy was noted. Methotrexate therapy was 
commenced at the age of six, and used alone and in combination with etretinate, but 
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neither regime gave good disease control. Hydroxyurea was ineffective. Oral 
prednisolone suppressed pustulation, however could not be sustained due to 
Cushingoid side effects. Deterioration of her skin was noted during her both 
pregnancies, consistent with a diagnosis of impetigo herpetiformis, warranting 
treatment with ciclosporin during the 2nd-3rd trimester in her first pregnancy and an 
elective termination of her second pregnancy. In addition to the physical morbidity 
the patient had been treated for depression relating to her cutaneous disease.  
      Recombinant soluble TNF-alpha receptor treatment was chosen at the age of 
30, given the severity of her disease (Figures 1b-c). Following treatment with 
Etanercept at a dose of 25 mg subcutaneously twice weekly, her cutaneous disease 
activity was brought under control. Methotrexate and prednisolone were weaned 
successfully and the patient had normal nail growth for the first time. After 11 months 
of treatment, she demonstrated plaque psoriasis without pustulation. The patient was 
then treated with Adalimumab 40mg subcutaneously every 2 weeks, with improved 
control and has continued on this for the last 6 years. There have been no hospital 
admissions for the last 7 years. 
    By contrast, the proband’s sister who had never previously had skin disease, 
first developed widespread pustular psoriasis at the age of 34 warranting hospital 
admission. Her clinical history was negative for antecedent infection, medication use 
or pregnancy. She was admitted to hospital and managed with topical therapy, 
prompting resolution of the rash after 12 days.  She has subsequently had minimal 
disease affecting the scalp for a 6-month period. Notably she did not have oral 
pustules. 
 Mutation analysis of the IL36RN gene was performed given the phenotype, 
and demonstrated identical mutations (sequencing primers and conditions as 
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previously described1). Both sisters carried compound heterozygous mutations in 
exon 5 of the IL36RN: c.338C>T (p.Ser113Leu) and c.368C>T (p.Thr123Met) 
(Figure 2a). The c.338C>T mutation is a known founder mutation in European 
populations, whilst c.368C>T has been reported only in Japanese cases5, making 
this a novel finding in Europeans. As the mutation occurred at a CpG dinucleotide 
sequence, we postulate that the position c.368C of the IL36RN gene could be a 
mutational hot spot across different populations. PCR products were cloned to 
confirm that the two mutations resided on separate alleles.  
    In order to determine the biochemical effect of the missense mutation 
p.Thr123Met on the expression of IL-36Ra, we generated a N-terminal Flag-tagged 
expression vector for the p.Thr123Met mutant (Met-mutant) protein using the 
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) with the 
wild type (Wt) IL-36Ra-expression vector as a template.6 A p.Thr123Arg-Mut vector 
(Arg-mutant), containing a mutation known to influence IL-36Ra levels, was used as 
a positive control. Then we overexpressed the Wt, Met-mutant and Arg-mutant Flag-
IL-36Ra vectors in HEK293T cells, collected the cell lysate, and performed SDS-
PAGE separation of proteins followed by immunoblotting with mouse monoclonal 
anti-Flag M2 antibody (diluted 1:1,000; Sigma-Aldrich, St. Louis, MO). Similar to the 
Arg-mutant of IL-36Ra protein, expression of the Met-mutant was markedly reduced 
as compared to the Wt, suggesting an instability of the Met-mutant IL-36Ra protein 
(Figure 2b).6 
   To investigate the functional effect of this instability, we performed reporter gene 
assays using the IL8 promoter in HeLa cells as described previously.6 The Wt IL-
36Ra protein significantly repressed the promoter activity induced by IL-36γ and IL-
1RL2 (Figure 2c), whereas neither the Met-mutant nor the Arg-mutant IL-36Ra 
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proteins reduced the activity at all (p<0.01; students t-test), consistent with the 
mutation resulting in loss of function (Figure 2c).  
    To improve our understanding of how the mutation may have an effect on tertiary 
protein structure, we performed molecular modeling of the patient’s mutation 
(Thr123->Met) (Figure 2d). Thr123 is predicted to be situated in loop10 of IL-36Ra, 
which is a structural element for a core hydrophobic patch, where a large number of 
amino acid residues are densely embedded. The mutation into methionine at 
Thr123, which has bulkier side chain than threonine, is likely to cause steric clashing 
with adjacent amino acid residues. Furthermore the mutation is predicted to disrupt 
the hydrophobic interaction and hydrogen bond network contributing to the 
stabilisation of IL-36Ra conformation, resulting in protein misfolding. Taken together 
with the overexpression and reporter studies, and previous clinical data of changes 
at this residue, these data support the finding that the c.368C>T mutation in our 
patient is pathogenic. 
We present this case to highlight the strikingly distinct phenotypes seen in 2 IL36RN 
mutation carriers from the same non-consanguineous pedigree. Homozygous 
carriers of previously identified IL36RN mutations across families have been 
observed to have a range of age of presentations, that suggest further genetic and/or 
environmental risk factors may influence the age of onset3 (Supplementary Table 
1b). Comparison within a family, despite the caveats associated with smaller 
numbers of patients, control for some of this variation and is informative in our 
understanding of this disease. We also highlight enoral pustulation that was seen in 
our patient and has been recognised by Navarini et al.7 as a useful indicator of 
IL36RN mutations.  
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Figure Legends 
 
Fig 1. Clinical features and histopathological findings of the patient.  (a) The proband 
seen at age 6, with generalised pustular lesions seen on the torso and legs, on a 
background of erythroderma. (b) The proband prior to starting anti-TNF therapy at 
age 30, with a close up image (c) highlighting the pustulation and superficial 
desquamation seen. (d) A dense neutrophillic infiltrate seen in the epidermis in a skin 
biopsy of a pustule taken at age 6. 
 
Fig 2. Mutation analysis of IL36RN in both patients, and functional and molecular 
evidence supporting the pathogenicity of the T123R change. 
(a) Sanger sequencing analysis reveals compound heterozygous mutations in the 
proband’s DNA. Mutations are shown at 2 positions within IL36RN exon5 (“Patient”), 
c.338C>T and c.368C>T, which differs from the wild type sequence (“wild type”). 
Single allele analysis, carried out by cloning the PCR products followed by 
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sequencing, reveals the presence of the c.338 C>T mutation  “Allele a” and the 
c.368C>T on the other chromosome, “Allele b”. (b) Expression of the p.Thr123Met 
mutant IL-36Ra protein is severely impaired as compared to that of the wild type (Wt) 
IL-36Ra in HEK293T cells. All constructs were verified by direct sequencing.  Beta-
actin was blotted as a normalization control. (c) IL8 promoter-reporter gene assays 
demonstrate loss-of-function of the p.Thr123Met mutant IL-36Ra protein in HeLa 
cells. The IL8 promoter activity induced by IL-36γ and IL-1RL2 was significantly 
(p<0.01; students t-test) downregulated by the wild type (Wt) IL-36Ra, but not by the 
p.Thr123Met or the p.Thr123Arg mutant IL-36Ra. ). All experiments were performed 
in triplicate and repeated three times. The error bar indicates standard error of the 
mean of a single representative experiment. (N.S. not significant). (d) Cartoon 
diagrams of the core hydrophobic patch in the human IL-36Ra protein. The three-
dimensional structure of human IL-36Ra was modelled (Swiss model; 
http://swissmodel.expasy.org/) 8,9using a reported murine IL-1F5 structure (PDB ID: 
1MD6 10) as a template. The predicted structure was generated using Pymol v0.99 
(DeLano Scientific LLC, San Carlos, CA). Three β-hairpins of IL-36Ra are shown in 
purple (residues 1-46), green (residues 47-104), and orange (residues 105-155) 
ribbon representations. Amino acid residues that contribute to the stability of the 
conformation of IL-36Ra that interact with Thr123 are highlighted by stick 
presentations in red and blue. Suggested hydrogen bonds between these residues 
are shown as dotted lines.  
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(c) (d)
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